Objective: To evaluate the efficacy of clarithromycin alone in comparison with the combination of clarithromycin and cefuroxime in the treatment of nonhospitalized patients with community-acquired pneumonia (CAP) in a Mediterranean population. Methods: CAP was defined as the acute onset of fever (>38°C) with pulmonary opacity on chest roentgenogram. The American Thoracic Society (ATS) criteria (1993) were used to decide on patient hospitalization. Ninety subjects, of whom 53 (59%) were men, with a mean age (± SD) of 38 ± 15 years, were randomized: 45 received clarithromycin 500 mg b.i.d. orally for 14 days (CL group), and 45 received clarithromycin plus cefuroxime 500 mg b.i.d. orally for 7 days (CLCE group). Patients were monitored with clinical, radiological, and laboratory controls at 3 and 21 days. There were no significant differences between the two groups with regard to demographic, clinical, physical and laboratory data. Results: The mean time to defervescence was 2.4 ± 1.4 and 2.4 ± 1.5 days, respectively. Chest roentgenogram clearance was complete in all cases, without statistically significant differences in the time to resolution between both arms. Side effects were mild (no significant differences between groups): 5 patients in the CL group and 3 in the CLCE group showed gastrointestinal symptoms. Two patients (2.2%), both in the CLCE group, needed hospital admission during follow-up, but all 90 patients showed an excellent outcome. A causative agent was determined in 25 cases (28%). Legionella pneumophila, Streptococcus pneumoniae, and Mycoplasma pneumoniae were the most frequent pathogens. Conclusion: Empirical treatment of outpatient CAP with clarithromycin can be considered adequate in the Mediterranean area, independently of the microbiological etiology. ATS criteria for admitting patients with CAP are appropriate in this population.

1.
Garibaldi RA: Epidemiology of community-acquired respiratory tract infections in adults. Am J Med 1985;78(suppl 6B):32–37.
2.
Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG: Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987;i:671–674.
3.
Marrie TJ: Community-acquired pneumonia. Clin Infect Dis 1994;18:501–515.
4.
Ortqvist A, Hedlund J, Grillner L, Jalonen E: Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J 1990;3:1105–1113.
5.
Blanquer J, Blanquer R, Borras R, Nauffal D, Morales P, Menendez R, Subias I, Herrero L, Redon J, Pascual J: Aetiology of community-acquired pneumonia in Valencia, Spain: A multicentre prospective study. Thorax 1991;46:508–511.
6.
Fang G, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR, Yee YC, Rihs JD, Vickers RM: New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990;69:307–316.
7.
Berntsson E, Lagergard T, Strannegard O, Trollfors B: Etiology of community-acquired pneumonia in outpatients. Eur J Clin Microbiol 1986;5:446–447.
8.
Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH: Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet 1993;341:511–514.
9.
British Thoracic Society and the Public Health Laboratory Service: Community-acquired pneumonia in adults in British hospitals in 1982–1983: A survey of etiology, mortality, prognostic factors and outcome. Q J Med 1987;239:195–200.
10.
Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN: Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. Am J Med 1996;101:508–515.
11.
Burman LA, Trollfors B, Andersson B, Henrichsen J, Juto P, Kallings I, Lagergard T, Mollby R, Norrby R: Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special reference to antibodies against pneumococcal antigens. J Infect Dis 1991;163:1087–1093.
12.
Karalus NC, Cursons RT, Leng RA, Mahood CB, Rothwell RP, Hancock B, Cepulis S, Wawatai M, Coleman L: Community-acquired pneumonia: Aetiology and prognostic index evaluation. Thorax 1991;46:413–418.
13.
Pareja A, Bernal C, Levya A, Piedrola G, Maroto MC: Etiologic study of patients with community-acquired pneumonia. Chest 1992;101:1207–1210.
14.
American Thoracic Society Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418–1426.
15.
Mandell LA: Community-acquired pneumonia. Etiology, epidemiology and treatment. Chest 1995;108:35s–42s.
16.
Dorca J, Bello S, Blanquer J, de Celis R, Molinos L, Torres A, Verano A, Zalacain R: Normativa SEPAR sobre diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Arch Bronconeumol 1997;33:240–246.
17.
Murray PR, Washington JA: Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc 1975;50:339–344.
18.
Rein MF, Gwaltney JH, O’Brien WM, Jennings RH, Mandell GL: Accuracy of Gram’s stain in identifying pneumococci in sputum. JAMA 1978;239:2671–2673.
19.
Bartlett JG, Brewer NS, Ryan KJ: Laboratory diagnosis of lower respiratory tract infections; in Washington JA (ed): Cumitech 7 (Cumulative Techniques and Procedures in Clinical Microbiology). Washington, American Society for Microbiology, 1987, pp 1–15.
20.
Edelstein PH: Improved semiselective medium for isolation of Legionella pneumophila from contaminated clinical and environmental specimens. J Clin Microbiol 1981;14:298–303.
21.
Wilkinson HW, Filkes BJ: Cruce DD: Indirect immunofluorescence test for diagnosis of Legionnaires’ disease: Evidence for serogroup diversity of Legionnaires’ disease bacterial antigen and for multiple specificity of human antibodies. J Clin Microbiol 1979;9:379–383.
22.
MacFarlane JT, Finch RG, Ward MJ, Macrae AD: Hospital study of adult community-acquired pneumonia. Lancet 1982;ii:255–258.
23.
Tillotson JR, Lerner AM: Pneumonias caused by Gram-negative bacilli. Medicine (Baltimore) 1986;45:65–76.
24.
Aubertin J, Dabis F, Fleurette J, Bornstein N, Salamon R, Brottier E, Brune J, Vincent P, Migueres J, Jover A: Prevalence of legionellosis among adults: A study of community-acquired pneumonia in France. Infection 1987;15:328–331.
25.
Granados A, Podzamczer D, Gudiol F, Manresa F: Pneumonia due to Legionella and pneumococcal pneumonia: Similarities and differences on presentation. Eur Respir J 1989;2:130–134.
26.
Borrás R, Blanquer J, Millan E, Prat J, Sanfeliu P, Garcia de Lomas J: Prevalencia de anticuerpos anti-legionella pneumophila serogrupo 1 en la regíon valenciana. Enferm Infecc Microbiol Clin 1987;5:462–464.
27.
Blasi F, Cosentini R, Legnani D, Denti F, Allegra L: Incidence of community-acquired pneumonia caused by Chlamydia pneumoniae in Italian patients. Eur J Clin Microbiol Infect Dis 1993;12:696–699.
28.
Pallarés R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, Martin R, Gudiol F: Resistance to penicillin and cephalosporins and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474–480.
29.
Kingman S: Resistance a European problem, too. Science 1994;264:363–365.
30.
Sinberkoff MS: Drug-resistant pneumococcal infections in the United States. A problem for clinicians, laboratories, and public health. JAMA 1994;271:1875–1876.
31.
Manresa F, Dorca J, Gudiol F, et al: Procaine penicillin is still appropriate for pneumococcal pneumonia. Thorax 1994;49:1067P–1068P.
32.
Doern GV, Brueggemann A, Holley HP Jr, Rauch AM: Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40:1208–1213.
33.
Almirante B: Macrólidos: Viejos antibióticos para nuevas indicaciónes terapeúticas. Med Clin (Barc) 1995;104:139–141.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.